DLBCL – Does the Molecular Classification Really Inform Therapy?


Upon viewing this session, you will be able to:
• Assess data from recent randomized studies in DLBCL that have targeted cell of origin.
• Determine which patients with DLBCL are most likely to benefit from novel agents targeting molecular subtypes of DLBCL.
• Review perspectives regarding next steps in investigating how molecular biology of DLBCL could inform personalized therapy.


  • Kieron Dunleavy, MD, George Washington University


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top